Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Novel Regimens Show Continued Improvements in Newly Diagnosed Myeloma

March 9th 2020

The frontline treatment of patients with multiple myeloma continues to evolve with novel, multidrug regimens that are leading to higher, deeper, and more durable responses, as well as increased rates of minimal residual disease negativity.

Frontline Elotuzumab Triplet Misses PFS Endpoint in Multiple Myeloma

March 9th 2020

The addition of elotuzumab to lenalidomide and dexamethasone did not show a statistically significant improvement in progression-free survival compared with lenalidomide/dexamethasone alone in patients with newly diagnosed, previously untreated, transplant-ineligible multiple myeloma.

Research With BCMA-Targeted Agents, Venetoclax Appears Promising in Myeloma

March 9th 2020

Gareth J. Morgan, MD, PhD, discusses ongoing research of BCMA-targeted therapies, as well as the use of venetoclax in the myeloma treatment paradigm.

Research With BCMA-Targeted Agents, Venetoclax Appears Promising in Myeloma

March 7th 2020

Gareth J. Morgan, MD, PhD, discusses ongoing research of BCMA-targeted therapies, as well as the use of venetoclax in the myeloma treatment paradigm.

Upfront Multidrug Regimens Prove Beneficial in Myeloma

March 6th 2020

Marc J. Braunstein, MD, PhD, expands on the 3- and 4-drug regimens that are showing promise in the multiple myeloma paradigm.

Venetoclax Poised to Have Role in Myeloma, Despite Safety Concerns

March 5th 2020

Robb S. Friedman, MD, examines the developing role of venetoclax in relapsed/refractory multiple myeloma, based on the BELLINI results, and shares his anecdotal experience with the drug in the community setting.

BCMA Emerges as Hot Target in Myeloma, With CARs Leading the Way

March 5th 2020

Investigators have turned their attention to B-cell maturation antigen, which offers an ideal target for multiple myeloma therapy because of its restricted expression pattern.

Isatuximab Lead Investigator Explains Significance of FDA Approval in Myeloma

March 5th 2020

Paul G. Richardson, MD, discusses the findings from the ICARIA-MM trial and the clinical implications of isatuximab’s FDA approval in multiple myeloma.

Dr. Raje on the Efficacy of Belantamab Mafodotin in Multiple Myeloma

March 5th 2020

Noopur Raje, MD, discusses the utility of belantamab mafodotin in the treatment of patients with multiple myeloma.

Triplets Target Lenalidomide-Refractory Myeloma Subgroup

March 5th 2020

Faith E. Davies, MD, discusses pivotal research in relapsed/refractory myeloma and precision medicine efforts in the field.

Dr. O'Donnell on Unanswered Questions in Multiple Myeloma

March 4th 2020

Betsy O’Donnell, MD, discusses unanswered questions in multiple myeloma.

Novel Combos Thrive in Myeloma, But Challenges Remain

March 3rd 2020

James Weitzman, MD, discusses progress in the multiple myeloma treatment paradigm and what challenges remain.

Penn Investigator Sees Promises and Challenges in Myeloma Target

March 3rd 2020

Adam D. Cohen, MD, discusses the prospects for BCMA-targeting options in multiple myeloma.

Dr. Branagan on Tandem Transplants in Multiple Myeloma

March 3rd 2020

Andrew Branagan, MD, discusses the research tandem transplants in patients with high-risk multiple myeloma.

Dr. Richardson on the FDA Approval of Isatuximab in Relapsed/Refractory Myeloma

March 3rd 2020

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the FDA approval of isatuximab-irfc (Sarclisa) for use in combination with pomalidomide (Pomalyst) and dexamethasone in relapsed/refractory multiple myeloma.

Selinexor Regimen Improves PFS in Relapsed/Refractory Myeloma

March 2nd 2020

Selinexor in combination with bortezomib and low-dose dexamethasone led to a statistically significant increase in progression-free survival compared with bortezomib/dexamethasone alone in patients with multiple myeloma who have received 1 to 3 prior lines of therapy.

Pivotal Studies Provide New Path in High-Risk Smoldering Myeloma

March 2nd 2020

The diagnosis and management of smoldering multiple myeloma is an area of tremendous focused research and change over the past decade, with trials yielding intriguing findings that have the potential to change practice.

Next Chapter Begins With CAR T-Cell Therapy in Myeloma

March 1st 2020

Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.

Dr. Lonial on High-Risk Patients With Smoldering Multiple Myeloma

February 28th 2020

Sagar Lonial, MD, FACP, discusses how the treatment landscape has evolved for patients with smoldering multiple myeloma.

Expert Highlights Advantage of Triplet Therapies in Relapsed/Refractory Myeloma

February 28th 2020

Andrew Yee, MD, reflects on recent clinical trials in multiple myeloma that focused on novel multidrug regimens.